Tiziana Life Sciences Plc Covid-19 Treatment

NASDAQ:TLSA   Tiziana Life Sciences Ltd
Thinly traded nano cap Tiziana Life Sciences (NASDAQ:TLSA) is the latest coronavirus play. Shares are up 306% premarket on average volume in reaction to its announcement that candidate TZLS-501 may be a potential treatment for COVID-19 patients at risk of respiratory failure.

The company says it plans to administer TZLS-501, an interleukin 6 (IL-6)-inhibiting monoclonal antibody, using a proprietary formulation technology, adding that excess production of IL-6 is a key driver of chronic inflammation and is believed to play a key role in severe lung damage seen with COVID-19 infection and acute respiratory illness.
Source seekignalpha

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Email Newsletter:

2) Text Message Notifications:

3) Telegram:

4) Follow Us on our Social Networks

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.